60 related articles for article (PubMed ID: 19935379)
1. BAFF may modulate the rate of B-cell repopulation after rituximab therapy for acute renal transplant rejection.
Zarkhin V; Li L; Sarwal MM
Transplantation; 2009 Nov; 88(10):1229-30. PubMed ID: 19935379
[No Abstract] [Full Text] [Related]
2. Targeting B cells and antibody in transplantation.
Clatworthy MR
Am J Transplant; 2011 Jul; 11(7):1359-67. PubMed ID: 21668625
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive Medications.
Wiseman AC
Clin J Am Soc Nephrol; 2016 Feb; 11(2):332-43. PubMed ID: 26170177
[TBL] [Abstract][Full Text] [Related]
4. Short-term Immunopathological Changes Associated with Pulse Steroids/IVIG/Rituximab Therapy in Late Kidney Allograft Antibody Mediated Rejection.
Degner KR; Wilson NA; Reese SR; Parajuli S; Aziz F; Garg N; Mohamed M; Singh T; Mandelbrot DA; Panzer SE; Redfield RR; Van Hyfte K; Zhong W; Hidalgo LG; Djamali A
Kidney360; 2020 May; 1(5):389-398. PubMed ID: 34476406
[TBL] [Abstract][Full Text] [Related]
5. B cell-activating factor modulates the factor VIII immune response in hemophilia A.
Doshi BS; Rana J; Castaman G; Shaheen MA; Kaczmarek R; Butterfield JS; Meeks SL; Leissinger C; Biswas M; Arruda VR
J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33651716
[TBL] [Abstract][Full Text] [Related]
6. B Cell Immunity in Solid Organ Transplantation.
Karahan GE; Claas FH; Heidt S
Front Immunol; 2016; 7():686. PubMed ID: 28119695
[TBL] [Abstract][Full Text] [Related]
7. Clinical Significance of Pre- and Post-Transplant BAFF Levels in Kidney Transplant Recipients.
Min JW; Kim KW; Kim BM; Doh KC; Choi MS; Choi BS; Park CW; Yang CW; Kim YS; Oh EJ; Chung BH
PLoS One; 2016; 11(9):e0162964. PubMed ID: 27631619
[TBL] [Abstract][Full Text] [Related]
8. Preemptive CD20+ B cell Depletion Attenuates Cardiac Allograft Vasculopathy in CD154-Treated Monkeys.
Azimzadeh AM; Zhang T; Wu G; Kelishadi SS; Stoddard T; OʼNeill N; Nguyen BN; Welty E; Avon C; Higuchi M; Mitchell SL; Hershfeld A; Cheng XF; Kronfli A; Rybak E; Burdorf L; Pierson RN
Transplantation; 2017 Jan; 101(1):63-73. PubMed ID: 27362307
[TBL] [Abstract][Full Text] [Related]
9. Inflammation Causes Resistance to Anti-CD20-Mediated B Cell Depletion.
Laws LH; Parker CE; Cherala G; Koguchi Y; Waisman A; Slifka MK; Oberbarnscheidt MH; Obhrai JS; Yeung MY; Riella LV
Am J Transplant; 2016 Nov; 16(11):3139-3149. PubMed ID: 27265023
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers in kidney transplantation: From bench to bedside.
Townamchai N; Eiam-Ong S
World J Nephrol; 2015 Nov; 4(5):487-91. PubMed ID: 26558185
[TBL] [Abstract][Full Text] [Related]
11. The immunological footprint of CMV in HIV-1 patients stable on long-term ART.
Affandi JS; Montgomery J; Brunt SJ; Nolan D; Price P
Immun Ageing; 2015; 12():14. PubMed ID: 26435726
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing BAFF/APRIL with atacicept prevents early DSA formation and AMR development in T cell depletion induced nonhuman primate AMR model.
Kwun J; Page E; Hong JJ; Gibby A; Yoon J; Farris AB; Villinger F; Knechtle S
Am J Transplant; 2015 Mar; 15(3):815-22. PubMed ID: 25675879
[TBL] [Abstract][Full Text] [Related]
13. Rational clinical trial design for antibody mediated renal allograft injury.
Sandal S; Zand MS
Front Biosci (Landmark Ed); 2015 Jan; 20(4):743-62. PubMed ID: 25553476
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.
Kamburova EG; Koenen HJ; van den Hoogen MW; Baas MC; Joosten I; Hilbrands LB
PLoS One; 2014; 9(11):e112658. PubMed ID: 25393622
[TBL] [Abstract][Full Text] [Related]
15. Role of ELISPOT Assays in Risk Assessment Pre- and Post-Kidney Transplantation.
Zitzner JR; Tambur AR
Cells; 2012 May; 1(2):100-10. PubMed ID: 24710417
[TBL] [Abstract][Full Text] [Related]
16. Biologic agents in islet transplantation.
Gala-Lopez B; Pepper AR; Shapiro AM
Curr Diab Rep; 2013 Oct; 13(5):713-22. PubMed ID: 23918618
[TBL] [Abstract][Full Text] [Related]
17. Elevated pretransplantation soluble BAFF is associated with an increased risk of acute antibody-mediated rejection.
Banham G; Prezzi D; Harford S; Taylor CJ; Hamer R; Higgins R; Bradley JA; Clatworthy MR
Transplantation; 2013 Aug; 96(4):413-20. PubMed ID: 23842189
[TBL] [Abstract][Full Text] [Related]
18. B cell activating factor (BAFF) in the natural history of chronic hepatitis C virus liver disease and mixed cryoglobulinaemia.
Lake-Bakaar G; Jacobson I; Talal A
Clin Exp Immunol; 2012 Nov; 170(2):231-7. PubMed ID: 23039894
[TBL] [Abstract][Full Text] [Related]
19. Tolerogenic therapies in transplantation.
Page EK; Dar WA; Knechtle SJ
Front Immunol; 2012; 3():198. PubMed ID: 22826708
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum levels of B-cell activating factor in pediatric renal transplant patients.
Lehnhardt A; Dunst F; van Husen M; Loos S; Oh J; Eiermann T; Koch M; Kemper MJ
Pediatr Nephrol; 2012 Aug; 27(8):1389-95. PubMed ID: 22453734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
